| 摘要 |
<p>The present invention relates to a method for assessing Alzheimer's disease in vitro comprising measuring in a sample (e.g. body fluid) the level of one or more proteins of the group consisting of Neurofilament triplet M protein and Alpha-internexin, or a variant thereof, wherein an altered level of said one or more proteins, or a variant thereof, is indicative that said individual suffers from Alzheimer's Disease. Furthermore, the present invention relates to a method for monitoring the progression of the Alzheimer's disease in vitro comprising measuring in a sample (e.g. body fluid) the level of one or more proteins of the group consisting of Neurofilament triplet M protein and Alpha- internexin, or a variant thereof, wherein an altered level of said one or more proteins, or a variant thereof, compared with an earlier measurement of the level of said one or more proteins, or a variant thereof, is indicative for the progression of Alzheimer's disease.</p> |
